Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CMO Anna Eramo resigned effective June 15, 2026, transitioning to advisor and full-time consultant through September 15, 2026.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CMO Anna Eramo resigned effective June 15, 2026, transitioning to advisor and full-time consultant through September 15, 2026
- Company expects no material impact on clinical development activities or previously disclosed milestones
- Replacement search underway, with existing clinical development and operations teams overseeing ongoing trials
- Separation benefits include base salary through June 15, 2027 and 100% prorated 2026 target bonus
- 66,143 unvested option shares accelerate and become vested and exercisable September 15, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.